Table 3.

Summary of demographic and physical features of pathologically-proven sporadic and neurofibromatosis type 1-associated glomus tumors of the fingers and toes. Data on patients Leu-2 and Leu-3 excluded from "Combined NIH/Belgian/Hamburg experience" since they were previously reported[2] and thus accounted in "Previously reported NF1-associated glomus tumors." Includes data on NIH-5. Data on "Previously reported NF1-associated glomus tumors" from references listed in Table 1. Data on sporadic glomus tumors from van Geertruyden et al 1996 and Vasisht et al 2004.

Feature	Combined NIH/Belgian/Hamburg experience in pathologically proven glomus tumors	Previously reported NF1- associated glomus tumors (pathologically-proven)	Sporadic glomus tumors (data combined from van Geertruyden et al 1996 and Vasisht et al 2004)
Male:Female	2 M (15%); 11 F (85%)	2 M (29%); 5 F (71%)	11 M (16%); 59 F (84%)
Right:Left (Fingers and toes)	Right: 42%; Left: 58%	Right: 41%; Left: 59%	van Geertruyden: Right: 47%; Left: 53%; Vasisht: Right: 57%, Left: 42%
Location of tumor
Thumb (F1)	1 (5%)	2 (10%)	17 (24%)
F2	1 (5%)	3 (14%)	8 (11%)
F3	6 (32%)	5 (24%)	18 (26%)
F4	8 (42%)	7 (33%)	18 (26%)
F5	3 (16%)	4 (19%)	9 (13%)
Finger Totals	19 (100%)	21 (100%)	70 (1005)
Toes	1	1	0
Patients with multi-focal tumors	3/15 (20%)	5/6 (83%)	None
Years of symptoms prior to diagnosis	1 to 40+ years	Up to 20 years	1 to 40 years
Average age of diagnosis (yrs)	40 (combined, range 11–57); 54 (M, range: 50–57); 38 (F, range 11–57)	33 (combined, range 17 – 53); 40 years (M, range: 35–45); 31 years (F, range: 17–53)	van Geertruyden: 44 (combined, range 26–83); Vasisht: 43 (combined, range: 14–95); 40 (M, range: 28–72); 43 (F, range: 14–95)